Method for treating vascular-related disease
Inventors
Kim, Doo-Sik • Cho, Yang-Je • Yoo, Won-Il • Kwon, Oh-Woong • Jang, Jin-Wook • Lim, Hyeong-Joon • Kwon, Soo-Mee
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-RE48023-E1
Publication Date
2020-06-02
Expiration Date
Abstract
A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
Core Innovation
The invention describes Xaa-Gly-Asp peptides, including specified RGD/KGD sequences, and peptide SEQ ID NO:8, for treatment of vascular-related edema and ischemia. The described approach promotes normal angiogenesis and stabilizes vessel walls to reduce blood-vessel leakage. The problem addressed is edema or ischemia associated with blood leakage from vessel walls, vessel damage, or abnormal angiogenesis.
The description reports effects including increased corneal vessel growth, reduced abnormal retinal angiogenesis and leakage, preservation of retinal tissue, and improved wound closure. It also reports induced angiopoietin-1 secretion in cell and mouse-plasma assays. The described applications include ocular vascular disease, ulcers, and related conditions, with stem cells and VEGF or bFGF also discussed.
Claims Coverage
The three independent claims cover methods for treating vascular-related disease using specified peptides across three inventive features, addressing edema or ischemia caused by blood-vessel leakage, vessel damage, or abnormal angiogenesis.
SEQ ID NO:8 for vascular-related edema
Claim 1 covers administering a peptide consisting of the amino acid sequence of SEQ ID NO:8 to treat edema caused by blood leakage of blood vessel walls, damages of blood vessels, or abnormal angiogenesis. Dependent claims add administration of stem cells, including stem cells with an ability to differentiate into vascular endothelial cells.
Specified peptides for vascular-related edema or ischemia
Claim 4 covers administering a peptide selected from the amino acid sequences of SEQ ID NOs:1, 2, 5–7, 9, and 10 to treat edema or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels, or abnormal angiogenesis. Dependent claims specify associated conditions and add stem cells, VEGF or bFGF, and carrier-containing or injectable compositions.
SEQ ID NO:8 for vascular-related ischemia
Claim 12 covers administering a peptide consisting of the amino acid sequence of SEQ ID NO:8 to treat ischemia caused by blood leakage of blood vessel walls, damages of blood vessels, or abnormal angiogenesis. Dependent claims specify associated conditions and add stem cells, VEGF or bFGF, and carrier-containing or injectable compositions.
Together, the independent claims cover peptide-based treatment of vascular-related edema and ischemia, using either SEQ ID NO:8 or the specified peptide sequences, while dependent claims further define associated conditions, optional treatment components, and formulations.
Stated Advantages
Promotes normal angiogenesis and stabilizes vessel walls to reduce blood-vessel leakage.
The described studies report reduced abnormal retinal angiogenesis and leakage, preservation of retinal tissue, increased corneal vessel growth, and improved wound closure.
Cell and mouse-plasma assays report induced angiopoietin-1 secretion.
Documented Applications
Treatment of vascular-related edema or ischemia associated with blood-vessel leakage, vessel damage, or abnormal angiogenesis.
The claims identify diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, glaucoma, diabetic foot ulcer, bedsore, chronic ulcer, alopecia, and trichopoliosis associated with failure in normal capillary formation.
The description also identifies ocular vascular disease, ulcers, and wound healing as applications.
Interested in licensing this patent?